Veracyte, Inc.

Name: Veracyte, Inc. standardized financial statements, quarterly
Creator: Listed

VCYTNasdaqCIK 1384101HealthcareFiscal year ends Dec 31

Share this page

Link

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Revenue$150.3m, Q2 FY2026

Operating income$23.0m, Q2 FY2026

Net income$25.5m, Q2 FY2026

Veracyte, Inc., income statement, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Revenue	$m	90.1	98.2	96.8	114	116	119	114	130	132	141	139	150
Cost of revenue	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Gross profit	$m	57.7	64.8	62.5	77.9	79.0	78.8	79.5	89.8	91.3	102	101	109
Research and development	$m	13.3	18.7	16.0	16.5	17.6	19.3	17.7	16.3	16.0	20.8	27.1	29.4
Operating income	$m	(31.7)	(35.5)	(4.7)	4.6	12.0	4.2	2.9	(5.3)	22.9	37.2	22.6	23.0
Interest expense	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Income tax	$m	(0.2)	(2.2)	(0.0)	1.6	1.7	(1.7)	0.4	2.2	(0.2)	(0.5)	1.3	1.0
Net income	$m	(29.6)	(28.3)	(1.9)	5.7	15.2	5.1	7.0	(1.0)	19.1	41.1	28.7	25.5
Diluted EPS	$ per share	(0.41)	not reported	(0.02)	0.07	0.19	not reported	0.09	(0.01)	0.24	not reported	0.35	0.31
Basic EPS	$ per share	(0.41)	not reported	(0.02)	0.07	0.20	not reported	0.09	(0.01)	0.24	not reported	0.36	0.32

Balance sheet

Cash and equivalents$299.5m, Q2 FY2026

Shareholders' equity$1.39bn, Q2 FY2026

Veracyte, Inc., balance sheet, quarterly
Line item	Unit	Q3 FY20232023-09-30	FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Cash and equivalents	$m	202	216	209	236	274	239	186	219	316	363	263	300
Current assets	$m	271	286	290	321	357	372	383	415	449	488	522	575
Total assets	$m	1,125	1,115	1,200	1,234	1,275	1,300	1,315	1,344	1,368	1,406	1,436	1,486
Current liabilities	$m	57.3	61.2	58.1	72.3	70.3	78.6	75.1	76.4	72.2	59.9	56.1	62.7
Total liabilities	$m	70.9	70.8	81.4	102	99.0	124	120	123	110	96.4	92.0	98.0
Long-term debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Current portion of debt	$m	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported	not reported
Shareholders' equity	$m	1,054	1,044	1,119	1,133	1,176	1,176	1,195	1,221	1,258	1,310	1,344	1,388

Cash flow

Operating cash flow$45.8m, Q2 FY2026

Capital expenditure$2.9m, Q2 FY2026

Veracyte, Inc., cash flow, quarterly
Line item	Unit	Q3 FY20232023-09-30	Q4 FY20232023-12-31	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q4 FY20242024-12-31	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q4 FY20252025-12-31	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Operating cash flow	$m	14.2	15.6	(9.0)	29.6	30.0	24.5	5.4	33.6	44.8	52.6	35.2	45.8
Capital expenditure	$m	2.8	2.5	2.1	2.8	2.2	4.1	1.8	1.3	2.8	3.8	3.0	2.9

Diluted shares (weighted)82.06m, Q2 FY2026

Veracyte, Inc., shares, quarterly
Line item	Unit	Q3 FY20222022-09-30	Q1 FY20232023-03-31	Q1 FY20232023-06-30	Q3 FY20232023-09-30	Q1 FY20242024-03-31	Q2 FY20242024-06-30	Q3 FY20242024-09-30	Q1 FY20252025-03-31	Q2 FY20252025-06-30	Q3 FY20252025-09-30	Q1 FY20262026-03-31	Q2 FY20262026-06-30
Diluted shares (weighted)	m shares	71.7	72.2	72.5	72.8	74.8	77.2	78.5	80.1	78.4	79.7	81.3	82.1

Shares outstanding: 80.39m at Jul 27, 2026, from the cover of the 10-Q filed Jul 31, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:38 ET. Listed shows no prices and gives no investment advice.